Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $40.78

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $40.78.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Jefferies Financial Group boosted their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, May 20th. HC Wainwright boosted their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Piper Sandler boosted their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, Chardan Capital boosted their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, May 21st.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $31.79 on Thursday. The business’s 50 day simple moving average is $28.46 and its two-hundred day simple moving average is $23.25. The stock has a market capitalization of $2.78 billion, a P/E ratio of -8.01 and a beta of 1.06. Dyne Therapeutics has a one year low of $6.40 and a one year high of $35.98.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting analysts’ consensus estimates of ($0.81). Sell-side analysts expect that Dyne Therapeutics will post -3.03 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26. Following the sale, the chief operating officer now directly owns 154,062 shares in the company, valued at $4,355,332.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at $3,479,624.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Susanna Gatti High sold 2,738 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the sale, the chief operating officer now directly owns 154,062 shares in the company, valued at $4,355,332.74. The disclosure for this sale can be found here. Insiders have sold 162,183 shares of company stock worth $5,098,485 over the last ninety days. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Wetzel Investment Advisors Inc. bought a new position in shares of Dyne Therapeutics during the first quarter valued at $28,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after purchasing an additional 5,541 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Dyne Therapeutics during the first quarter valued at $214,000. Finally, SG Americas Securities LLC bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at $172,000. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.